HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells

Ji,Meiying; Lee,Eun Jeoung; Kim,Ki Bae; Kim,Yangmi; Sung,Rohyun; Lee,Sang-Jeon; Kim,Don Soo; Park,Seon Mee

doi:10.3892/or.2015.3879

HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells

Authors:
- Meiying Ji
- Eun Jeoung Lee
- Ki Bae Kim
- Yangmi Kim
- Rohyun Sung
- Sang-Jeon Lee
- Don Soo Kim
- Seon Mee Park
View Affiliations

Affiliations: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju 361-711, Republic of Korea, Department of Physiology, Chungbuk National University College of Medicine, Cheongju 361-711, Republic of Korea, Department of Pathology, Chungbuk National University College of Medicine, Cheongju 361-711, Republic of Korea, Department of General Surgery, Chungbuk National University College of Medicine, Cheongju 361-711, Republic of Korea, Department of Orthopedic Surgery, Chungbuk National University College of Medicine, Cheongju 361-711, Republic of Korea
Published online on: March 23, 2015 https://doi.org/10.3892/or.2015.3879
Pages: 2299-2308

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effects of histone deacetylase (HDAC) inhibitors on epithelial-mesenchymal transition (EMT) differ in various types of cancers. We investigated the EMT phenotype in four colon cancer cell lines when challenged with HDAC inhibitors trichostatin A (TSA) and valproic acid (VPA) with or without transforming growth factor-β1 (TGF-β1) treatment. Four colon cancer cell lines with different phenotypes in regards to tumorigenicity, microsatellite stability and DNA mutation were used. EMT phenotypes were assessed by the expression of E-cadherin and vimentin using western blot analysis, immunofluorescence, quantitative real-time RT-PCR following treatment with TSA (100 or 200 nM) or VPA (0.5 mM) with or without TGF-β1 (5 ng/ml) for 24 h. Biological EMT phenotypes were also evaluated by cell morphology, migration and invasion assays. TSA or VPA induced mesenchymal features in the colon carcinoma cells by a decrease in E-cadherin and an increase in vimentin expression at the mRNA and protein levels. Confocal microscopy revealed membranous attenuation or nuclear translocation of E-cadherin and enhanced expression of vimentin. These responses occurred after 6 h and increased until 24 h. Colon cancer cells changed from a round or rectangular shape to a spindle shape with increased migration and invasion ability following TSA or VPA treatment. The susceptibility to EMT changes induced by TSA or VPA was comparable in microsatellite stable (SW480 and HT29) and microsatellite unstable cells (DLD1 and HCT116). TSA or VPA induced a mesenchymal phenotype in the colon carcinoma cells and these effects were augmented in the presence of TGF-β1. HDAC inhibitors require careful caution before their application as new anticancer drugs for colon cancers.

View Figures

View References

1	Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG and Lee JS: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 44:11–24. 2012. View Article : Google Scholar : PubMed/NCBI
2	Tsai HL, Chu KS, Huang YH, Su YC, Wu JY, Kuo CH, Chen CW and Wang JY: Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol. 100:736–743. 2009. View Article : Google Scholar : PubMed/NCBI
3	Lee SJ, Choi SY, Kim WJ, Ji M, Lee TG, Son BR, Yoon SM, Sung R, Lee EJ, Youn SJ and Park SM: Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients. Diagn Pathol. 8:992013. View Article : Google Scholar
4	He X, Chen Z, Jia M and Zhao X: Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis. PLoS One. 8:e708582013. View Article : Google Scholar : PubMed/NCBI
5	Findlay VJ, Wang C, Watson DK and Camp ER: Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther. 21:181–187. 2014. View Article : Google Scholar : PubMed/NCBI
6	Mariadason JM: HDACs and HDAC inhibitors in colon cancer. Epigenetics. 3:28–37. 2008. View Article : Google Scholar : PubMed/NCBI
7	Chen X, Wong P, Radany E and Wong JY: HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm. 24:689–699. 2009. View Article : Google Scholar : PubMed/NCBI
8	Meng J, Zhang HH, Zhou CX, Li C, Zhang F and Mei QB: The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways. Oncol Rep. 28:384–388. 2012.PubMed/NCBI
9	Hsu YF, Sheu JR, Lin CH, Yang DS, Hsiao G, Ou G, Chiu PT, Huang YH, Kuo WH and Hsu MJ: Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells. Biochim Biophys Acta. 1820:104–115. 2012. View Article : Google Scholar
10	Xiong H, Du W, Zhang YJ, Hong J, Su WY, Tang JT, Wang YC, Lu R and Fang JY: Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog. 51:174–184. 2012. View Article : Google Scholar
11	Habold C, Poehlmann A, Bajbouj K, Hartig R, Korkmaz KS, Roessner A and Schneider-Stock R: Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis. J Cell Mol Med. 12:607–621. 2008. View Article : Google Scholar : PubMed/NCBI
12	Marchion D and Munster P: Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 7:583–598. 2007. View Article : Google Scholar : PubMed/NCBI
13	Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F and Gambacorti-Passerini C: Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. Int J Cancer. 124:1990–1996. 2009. View Article : Google Scholar : PubMed/NCBI
14	DI Fazio P, Montalbano R, Quint K, Alinger B, Kemmerling R, Kiesslich T, Ocker M and Neureiter D: The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models. Oncol Lett. 5:127–134. 2013.
15	Shah P, Gau Y and Sabnis G: Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin. Breast Cancer Res Treat. 143:99–111. 2014. View Article : Google Scholar
16	Srivastava RK, Kurzrock R and Shankar S: MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther. 9:3254–3266. 2010. View Article : Google Scholar : PubMed/NCBI
17	Taylor MD, Liu Y, Nagji AS, Theodosakis N and Jones DR: Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. J Thorac Cardiovasc Surg. 139:1224–1232. 2010. View Article : Google Scholar : PubMed/NCBI
18	Meng F, Sun G, Zhong M, Yu Y and Brewer MA: Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer. Br J Cancer. 108:579–586. 2013. View Article : Google Scholar : PubMed/NCBI
19	Kaimori A, Potter JJ, Choti M, Ding Z, Mezey E and Koteish AA: Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology. 52:1033–1045. 2010. View Article : Google Scholar : PubMed/NCBI
20	Xiao W, Chen X, Liu X, Luo L, Ye S and Liu Y: Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells. J Cell Mol Med. 18:646–655. 2014. View Article : Google Scholar : PubMed/NCBI
21	Chen X, Xiao W, Chen W, Luo L, Ye S and Liu Y: The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells. Cell Death Dis. 4:e8842013. View Article : Google Scholar : PubMed/NCBI
22	Yoshikawa M, Hishikawa K, Marumo T and Fujita T: Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol. 18:58–65. 2007. View Article : Google Scholar
23	Kong D, Ahmad A, Bao B, Li Y, Banerjee S and Sarkar FH: Histone deacetylase inhibitors induce epithelial-to-mesenchymal tranasition in prostate cancer cells. PLoS One. 7:e450452012. View Article : Google Scholar
24	Giudice FS, Pinto DS Jr, Nör JE, Squarize CH and Castilho RM: Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One. 8:e586722013. View Article : Google Scholar : PubMed/NCBI
25	Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, Wang H, Cai SH and Du J: Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochim Biophys Acta. 1833:663–671. 2013. View Article : Google Scholar
26	Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, Park DY, Iafrate AJ, Zukerberg LR and Chung DC: Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology. 138:1406–1417. 2010. View Article : Google Scholar :
27	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
28	Wu Y, Zhang X, Salmon M and Zehner ZE: The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression. Genes Cells. 12:905–918. 2007. View Article : Google Scholar : PubMed/NCBI
29	Uchida H, Maruyama T, Nishikawa-Uchida S, Oda H, Miyazaki K, Yamasaki A and Yoshimura Y: Studies using an in vitro model show evidence of involvement of epithelial-mesenchymal transition of human endometrial epithelial cells in human embryo implantation. J Biol Chem. 287:4441–4450. 2012. View Article : Google Scholar :
30	Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
31	Gujral TS and MacBeath G: A system-wide investigation of the dynamics of Wnt signaling reveals novel phases of transcriptional regulation. PLoS One. 5:e100242010. View Article : Google Scholar : PubMed/NCBI
32	Elzagheid A, Algars A, Bendardaf R, Lamlum H, Ristamaki R, Collan Y, Syrjanen K and Pyrhonen S: E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol. 12:4304–4309. 2006.PubMed/NCBI
33	Céspedes MV, Larriba MJ, Pavón MA, Alamo P, Casanova I, Parreño M, Feliu A, Sancho FJ, Muñoz A and Mangues R: Site-dependent E-cadherin cleavage and nuclear translocation in metastatic colorectal cancer model. Am J Pathol. 177:2067–2079. 2010. View Article : Google Scholar
34	Han AC, Soler AP, Tang CK, Knudsen KA and Salazar H: Nuclear localization of E-cadherin expression in Merkel cell carcinoma. Arch Pathol Lab Med. 124:1147–1151. 2000.PubMed/NCBI
35	Moon KC, Cho SY, Lee HS, Jeon YK, Chung JH, Jung KC and Chung DH: Distinct expression patterns of E-cadherin and beta-catenin in signet ring cell carcinoma components of primary pulmonary adenocarcinoma. Arch Pathol Lab Med. 130:1320–1325. 2006.PubMed/NCBI
36	Gervais ML, Henry PC, Saravanan A, Burry TN, Gallie BL, Jewett MA, Hill RP, Evans AJ and Ohh M: Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. Lab Invest. 87:1252–1264. 2007. View Article : Google Scholar : PubMed/NCBI
37	Salahshor S, Naidoo R, Serra S, Shih W, Tsao MS, Chetty R and Woodgett JR: Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. Mod Pathol. 21:271–281. 2008. View Article : Google Scholar
38	Serra S, Salahshor S, Fagih M, Niakosari F, Radhi JM and Chetty R: Nuclear expression of E-cadherin in solid pseudopapillary tumors of the pancreas. JOP. 8:296–303. 2007.PubMed/NCBI
39	Ordonez NG: Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma. Hum Pathol. 34:749–755. 2003. View Article : Google Scholar : PubMed/NCBI
40	Robertson FM, Woodward WA, Pickei R, Ye Z, Bornmann W, Pal A, Peng Z, Hall CS and Cristofanilli M: Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. Cancer. 116:2760–2767. 2010. View Article : Google Scholar : PubMed/NCBI
41	Lei W, Zhang K, Pan X, Hu Y, Wang D, Yuan X, Shu G and Song J: Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition. Int J Biochem Cell Biol. 42:1489–1497. 2010. View Article : Google Scholar : PubMed/NCBI
42	Manoguerra AS, Erdman AR, Woolf AD, Chyka PA, Caravati EM, Scharman EJ, Booze LL, Christianson G, Nelson LS, Cobaugh DJ and Troutman WG: Valproic acid poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 46:661–676. 2008. View Article : Google Scholar
43	Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S and Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 11:71–76. 2005. View Article : Google Scholar